|
|
Article: DuPont Merck Adds Selegiline to Parkinson's Disease Portfolio
- Article from:
- PR Newswire
- Article date:
- August 5, 1996
CopyrightCOPYRIGHT 1996 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WILMINGTON, Del., Aug. 5 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company (DuPont Pharma) announced today that Carbex(TM) (selegiline HCl) Tablets, USP, have been cleared for marketing by the Food and Drug Administration as adjunctive therapy for managing Parkinson's disease symptoms.
CARBEX, which is available in tablet rather than capsule form is bioequivalent, and therefore, therapeutically equivalent to Eldepryl(R) (selegiline hydrochloride) tablets as indicated in the treatment of Parkinson's disease.
CARBEX will complement DuPont Pharma's established line of Parkinson's disease therapies, including Sinemet(R) CR (Carbidopa-Levodopa) ...